Abridge, an AI clinical assistant platform, secured a strategic investment from Eli Lilly and announced major expansions into insurance workflows and life sciences research, broadening its reach beyond medical transcription.

What happened: Abridge announced that pharma company Eli Lilly and Company made a strategic investment in the company (financial details not disclosed). The company unveiled a major platform expansion to integrate payer and life sciences workflows, connecting care delivery, payment, and evidence-based treatment. Abridge now works with 300 health systems and its technology supports more than 100 million conversations annually.

Why it matters: Abridge started as a medical transcription tool eight years ago and has steadily expanded into billing, prior authorization, and clinical decision-making. The new platform aims to align real-time documentation with real-time claims workflows, which could help health systems and payers reduce rework and speed up insurance approvals. The company is also partnering with organizations to help health systems identify potential clinical trial candidates at the point of care.

What to watch: Abridge is working with Availity to deploy AI-powered prior authorization that could speed up the process from months to minutes (announced in January). The company is also implementing enterprise-wide across Northwestern Medicine's hospitals and network, and has new partnerships with the American Diabetes Association, American Academy of Family Physicians, and American Heart Association to integrate medical evidence into clinical decision support.